Drug Profile

Amlodipine/Candesartan/Indapamide - Shin Poong Pharmaceutical

Alternative Names: SPC-3001; SPC 1001 Mid2; SPC-1001; SPC-4001; SPC-4002

Latest Information Update: 20 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shin Poong Pharmaceutical
Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Indoles; Sulfonamides; Tetrazoles
Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Diuretics; Symporter inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

20 Feb 2025 Shin Poong Pharmaceutical initiates enrolment in a phase II trial for Essential hypertension in South Korea (PO) (NCT06826872)
27 Jan 2023 Shin Poong Pharmaceutical completes a phase II trial in Essential hypertension in South Korea (NCT06212648)
25 Mar 2022 Phase-II clinical trials in Essential hypertension in South Korea (PO) (NCT06212648)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com